Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

How would you manage a slowly progressive benign brain tumor located near critical structures such as the optic chiasm/brainstem?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Colorado School of Medicine

This is a very common occurrence, except that frequently we don't have histology. For example, meningiomas in the region of the cavernous sinus are frequently diagnosed by imaging criteria. In any event, I recommend radiation therapy for slowly growing asymptomatic, presumed benign tumors that are n...

In patients getting concurrent chemo-immunotherapy for locally advanced cervix cancer, would you hold immunotherapy during the 2.5-3 weeks of brachytherapy?

2
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

Pembro is continued throughout the course of treatment. Initially, every 3 weeks for 5 cycles with concurrent chemo RT plus brachy and then every 6 weeks for 15.

For primary CNS lymphoma, when do you refer for whole brain radiation therapy (WBRT)?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Brigham and Women's Hospital

When data are limited, consensus guidelines tend to rely on the personal clinical experiences of the guideline committee members. That may explain the NCCN guidelines. Recently, remarkable progress has been noted in the treatment of CNS lymphoma with drugs alone. Ibrutinib is particularly effective ...

Are you comfortable combining relugolix with enzalutamide or abiraterone?

2
2 Answers

Mednet Member
Mednet Member
Medical Oncology · The University of Texas Health Science Center at San Antonio

I usually avoid these combinations. The challenge is that relugolix is not superior to other ADT methods in terms of efficacy (at least based on available data) but there are safety issues with considering these combinations. All three of these medications are substrates for similar enzymatic metabo...

When do you recommend post-operative radiation therapy for extracranial chondrosarcoma?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · The Ohio State University - James Cancer Hospital and Solove Research Institute

When an en bloc resection with negative surgical margins is not achieved. Typically, this means tumors of the axial rather than appendicular skeleton, as margins are typically wide in the latter. There is "oncolore" that chondrosarcomas are radioresistant tumors. This is likely true at lower pallia...

Do you offer APBI for patients with invasive disease if there is high grade DCIS present in the lumpectomy specimen?

5
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Allegheny Health Network, Pittsburgh

In these situations, I am still comfortable offering PBI to patients. DCIS is seen with invasive disease in a fair number of cases so this comes up frequently and as long as other criteria are met, I view this as appropriate for PBI.

When do you recommend postoperative radiation therapy for a ureter carcinoma?

5
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · David Geffen School of Medicine at UCLA

The role of postoperative radiotherapy for ureteral cancers (and, by extension/association renal pelvis cancers) is controversial. Patients who might stand the most to benefit from adjuvant radiotherapy are those with locally advanced disease; unfortunately, these patients have a high risk of distan...

What is your radiation approach/details for regionally involved prostate cancer (N1)?

9
4 Answers

Mednet Member
Mednet Member
Radiation Oncology

For intact cases, I usually attempt to deliver a single-phase plan with multiple dose levels in 28 fractions as detailed below:Elective Pelvic LN volume (CTVn1): 50.4 Gy/28 fx. In cases of N1 disease, I would usually include the common iliacs. When the GTVn is near the cranial field edge, I usually ...

How do you approach patients with stage III unresectable, combined histology NSCLC/SCLC?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Texas MD Anderson Cancer Center

For stage III lung cancer with mixed NSCLC and small-cell lung cancer, we treat patients with concurrent chemotherapy (cisplatin/etoposide every three weeks) and definitive radiotherapy (60-66 Gy in 30 fractions, QD), followed by adjuvant immunotherapy (durvalumab). The rationales are as follows: Ra...

When you do recommend conventional fractionation over moderate hypofractionation for prostate cancer?

17
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University School of Medicine

I am routinely using 2.5-3 Gy in patients with low, intermediate, and some high risk patients so I guess I am an early adopter (or a cavalier nutjob). The exclusion criteria from the two published non-inferiority trials of moderate hypofractionation that are relevant to this question are quoted more...